Trial reportThe Journal of allergy and clinical immunology2014
Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2 immunity, and a unique gastric transcriptome.
Trial report in The Journal of allergy and clinical immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 2 syntheses or guidelines pooled it, 180 citations in OpenAlex.
- AGA Clinical Practice Update on Esophageal Dysfunction Due to Disordered Immunity and Infection: Expert Review.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024Guideline
- Dupilumab Leads to Clinical Improvements including the Acquisition of Tolerance to Causative Foods in Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Disorders.Biomolecules · 2023Pooled it
- Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial.The lancet. Gastroenterology & hepatology · 2026Trial
- Benralizumab Completely Depletes Gastrointestinal Tissue Eosinophils and Improves Symptoms in Eosinophilic Gastrointestinal Disease.The journal of allergy and clinical immunology. In practice · 2022Trial
- Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Trial
- Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis.The New England journal of medicine · 2020Trial
- Molecular, endoscopic, histologic, and circulating biomarker-based diagnosis of eosinophilic gastritis: Multi-site study.The Journal of allergy and clinical immunology · 2020Trial
- Cadherin-26 Promotes Airway Remodeling via Stabilizing Epithelial Expression of the Epidermal Growth Factor Receptor in Asthma.Allergy, asthma & immunology research · 2026Article
- Eosinophilic gastrointestinal diseases.Nature reviews. Disease primers · 2026Review
- Three-dimensional modeling of sensory nerve architecture and eosinophil and mast cell interactions in eosinophilic gastrointestinal disease.Journal of leukocyte biology · 2026Article
- Characterization of pediatric eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis in a nationwide cohort.Journal of pediatric gastroenterology and nutrition · 2026Article
- Cadherin-26 Facilitates Transepithelial Migration of Eosinophils in Eosinophilic Chronic Rhinosinusitis.International forum of allergy & rhinology · 2026Article
- Omalizumab-Induced Remission and Steroid Withdrawal in Refractory Eosinophilic Gastroenteritis with Severe Hypereosinophilia: A Case Report.Clinical and experimental gastroenterology · 2026Article
- Dupilumab as a rescue therapy for steroid-dependent eosinophilic gastritis in a child unresponsive to elimination diet: a case report.Frontiers in pediatrics · 2026Article
- Incidental Splenic Leiomyoma in a Child Uncovered During Workup for Eosinophilic Gastroenteritis.Cureus · 2025Article
- Eosinophils Beyond the Esophagus: A Review of Non-EoE Eosinophilic Gastrointestinal Diseases.Gastroenterology & hepatology · 2025Article
- [Research progress on risk factors for poor prognosis in pediatric non-esophageal eosinophilic gastrointestinal disorder].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025Review
- Age-Dependent Clinical Manifestations of Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis.Journal of asthma and allergy · 2025Article
- Combined eosinophilic gastroenteritis and ulcerative colitis successfully treated by vedolizumab: a case report.Intestinal research · 2025Article
- Effective use of dupilumab for eosinophilic gastritis concomitant with severe asthma.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe definition of eosinophilic gastritis (EG) is currently limited to histologic EG based on the tissue eosinophil count.
objectiveWe aimed to provide additional fundamental information about the molecular, histopathologic, and clinical characteristics of EG.
methodsGenome-wide transcript profiles and histologic features of gastric biopsy specimens, as well as blood eosinophil counts, were analyzed in patients with EG and control subjects (n = 15 each).
resultsThe peak gastric antrum eosinophil count was 283 ± 164 eosinophils/×400 high-power field in patients with EG and 11 ± 9 eosinophils/×400 high-power field in control subjects (P = 6.1 × 10(-7)). Patients with EG (87%) had coexisting eosinophilic inflammation in multiple gastrointestinal segments; the esophagus represented the most common secondary site. Increased peripheral blood eosinophil counts (patients with EG: 1.09 ± 0.88 × 10(3)/μL vs control subjects: 0.09 ± 0.08 10(3)/μL, P = .0027) positively correlated with peak gastric eosinophil counts (Pearson r(2) = .8102, P < .0001). MIB-1(+) (proliferating), CD117(+) (mast cells), and FOXP3(+) (regulatory T cells, activated T cells, or both) cell counts were increased in patients with EG. Transcript profiling revealed changes in 8% of the genome in gastric tissue from patients with EG. Only 7% of this EG transcriptome overlapped with the eosinophilic esophagitis transcriptome. Significantly increased IL4, IL5, IL13, IL17, CCL26, and mast cell-specific transcripts and decreased IL33 transcripts were observed.
conclusionEG is a systemic disorder involving profound blood and gastrointestinal tract eosinophilia, TH2 immunity, and a conserved gastric transcriptome markedly distinct from the eosinophilic esophagitis transcriptome. The data herein define germane cellular and molecular pathways of EG and provide a basis for improving diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.